Cost-Effectiveness of Romiplostim As First-Line Primary Immune Thrombocytopenia (Itp) Treatment in Adult Splenectomised Patients Who are Refractory to Other Treatments and As Second-Line Itp Treatment in Adult Non-Splenectomised Patients Wh ...
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.383
https://www.valueinhealthjournal.com/article/S1098-3015(15)02459-6/fulltext
Title :
Cost-Effectiveness of Romiplostim As First-Line Primary Immune Thrombocytopenia (Itp) Treatment in Adult Splenectomised Patients Who are Refractory to Other Treatments and As Second-Line Itp Treatment in Adult Non-Splenectomised Patients Wh ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02459-6&doi=10.1016/j.jval.2015.09.383
First page :
A842
Section Title :
Research Podium Presentations - Session 1
Open access? :
No
Section Order :
2604